Table 3.

Safety endpoints.

Experiment	Treatment onset	Dose level (mg/kg)	Weight loss (g)	Mortality
Dose response	24 h preischemic	Vehicle	5.3 ± 0.5	0/6
				100	4.3 ± 0.6	0/6
				200	3.5 ± 0.4	1/8
				300	4.5 ± 0.5	2/9
Therapeutic window	1–6 h postischemic	Vehicle	4.9 ± 0.3	1/30
		1 h postischemic	200	5.7 ± 0.2	1/9
		3 h postischemic	200	5.2 ± 0.2	0/15
		6 h postischemic	200	5.6 ± 0.3	1/8
Female	1 h postischemic	Vehicle	2.9 ± 0.5	0/9
				200	3.5 ± 0.4	0/9
Aged (12 months)	1 h postischemic	Vehicle	4.2 ± 0.7	1/7
				200	3.4 ± 0.6	2/8
Diabetic (db/db)	1 h postischemic	Vehicle	3.8 ± 0.3	0/6
				200	3.8 ± 0.3	0/8
Atorvastatin (20 mg/kg)	1 h postischemic	Vehicle	3.3 ± 0.8	1/7
			200	5.7 ± 0.3*	1/7
Permanent ischemia	1 h postischemic	Vehicle	4.0 ± 0.3	2/12
				200	3.5 ± 0.3	6/15

All treatments were administered every 12 h via oral gavage until sacrifice at 48 h (24 h in permanent ischemia experiment). Please see and for details of experimental groups and protocols, and the treatment paradigms. Weight loss expressed as mean ± SEM.

^*P < 0.05 versus atorvastatin plus vehicle. Unpaired t-test or one-way ANOVA for weight loss, chi-square or Fisher’s exact test for mortality.